Photocure (OB:PHO) Stock Faces Margin Squeeze Despite Revenue Growth

Photocure came into this print with a stock that has slipped over the past week and quarter, even as its long term uro oncology pitch has been about steady profitable growth. Q2 cut across that story. The company reported revenue of NOK 142.5m with a small net loss after a very strong profit in Q1, as higher operating costs and business development spending squeezed margins.

For a market already cautious after a 19% decline over 90 days, this mix of solid top line progress and pressure on profitability is the headline investors are reacting to today.

Is Photocure now a rare bargain after a soft Q2 margin, or is the lower share price simply the market pricing in future earnings pressure? Compare that story to the valuation analysis for Photocure

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): NOK 142.5m vs. NOK 135.6m (up about 5%)
• Net Income (Q2 2026 vs. Q2 2025): loss of NOK 0.7m vs. profit of NOK 4.9m (moved back into loss)
• Basic EPS (Earnings Per Share, Q2 2026 vs. Q2 2025): loss of NOK 0.03 per share vs. earnings of NOK 0.18 per share (moved back into loss)
• Adjusted EBITDA Margin (Hexvix/Cysview core, Q2 2026 vs. Q2 2025): 19%. Management commentary indicates this was roughly flat year on year, suggesting the margin held broadly stable.

Prefer clean charts instead of another dense page of earnings figures and margins? View a visual overview of Photocure's recent profitability trends and overall financial picture in the company report for Photocure.

Photocure’s growth story still has support

For investors focused on the positive side of the Photocure story, Q2 still offers some support. Hexvix/Cysview revenue of NOK 140m and unit growth across North America and Europe point to an underlying business that is adding procedures and accounts. Adjusted EBITDA margin for the core franchise stayed at 19% in Q2 and improved year to date. The balance sheet holds NOK 162.4m of cash and no debt. That mix of growth, recurring procedure activity and a clean balance sheet keeps the long term profitable growth ambition at least directionally intact.

Profit pressure keeps the bear case alive

The cautious view also has fresh evidence to point to. Photocure swung from a strong Q1 profit to a small Q2 net loss, with reported EBITDA slipping into negative territory as operating expenses rose 21%. Business development spending tied to Vesica and other platform moves is weighing on reported margins today, even as adjusted EBITDA looks healthier. The share price has fallen about 19% over 90 days, which shows the market is already reacting to the near term earnings pressure and higher investment load.

Compare the internal progress Photocure highlights on procedures, margins and cash with how the market is already pricing the stock after its recent move to NOK 53.3. See the consensus price target analysis for Photocure to check whether analyst targets line up with that story or point in a different direction.

Stay Ahead With Simply Wall St

If the mix of revenue progress and margin pressure at Photocure has your attention, register for free with Simply Wall St and add it to a Watchlist to track share price moves against fair value and watch for a more attractive entry point. Once you are invested, keep your focus on what matters most by using the Portfolio Command Center which filters out noise and surfaces only key developments around earnings, risks and valuation. For a broader view on Photocure and similar stocks, tap into the Community to see how other investors are interpreting the same data. By spotting hidden catalysts and potential risks early, you give yourself a better chance to stay ahead of the market over the long term.

Seeking Alternatives Beyond Photocure Today

Fresh stock ideas can move from quiet to crowded fast. Use focused screeners to spot momentum, potential breakouts and dropping risks while it matters. Get in early.

• Spot resilient businesses before the crowd and scan 304 resilient stocks with low risk scores to aim for a balance between growth potential, steadier share price behaviour and stronger balance sheets.
• Ride structural themes with staying power and review 34 power grid technology and infrastructure stocks to explore opportunities that could benefit from ongoing upgrades in energy networks and grid technology while they are still under the radar for now.
• Back long term industrial shifts and review 8 top copper producer stocks to focus on companies that sit at the heart of electrification, data growth and infrastructure buildouts before momentum really starts flying.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com